MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference
MWN-AI** Summary
MediciNova, Inc., a biopharmaceutical company known for its focus on innovative therapies for inflammatory, fibrotic, and neurodegenerative diseases, is set to present at the upcoming H.C. Wainwright 27th Annual Global Investment Conference. The event will take place from September 8 to 10, 2025, at the Lotte New York Palace Hotel. MediciNova’s President and CEO, Dr. Yuichi Iwaki, and Chief Business Officer, Dr. David H. Crean, will deliver a corporate overview, which will be available on-demand on September 5, 2025, starting at 7:00 AM ET.
The live presentation can be accessed via the investor relations section of MediciNova's website, with a replay available for approximately 90 days following the event. Additionally, attendees will have the opportunity to engage in one-on-one meetings with Drs. Iwaki and Crean throughout the conference.
MediciNova is currently advancing a strong late-stage pipeline featuring two principal compounds, MN-166 (ibudilast) and MN-001 (tipelukast), both of which exhibit multiple mechanisms of action and favorable safety profiles. MN-166 is in Phase 3 trials for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM), and is poised for Phase 3 readiness for progressive multiple sclerosis (MS). This compound is also being evaluated in Phase 2 studies for Long COVID and substance dependence. On the other hand, MN-001 is currently in a Phase 2 trial for non-alcoholic fatty liver disease (NAFLD) after having been previously tested in idiopathic pulmonary fibrosis (IPF).
As it moves forward, MediciNova emphasizes the uncertainties inherent in clinical development, including funding risks and potential delays in regulatory approvals. For further inquiries, investors can contact Dr. Crean directly.
MWN-AI** Analysis
As MediciNova, Inc. (NASDAQ: MNOV) prepares to present at the H.C. Wainwright 27th Annual Global Investment Conference, investors should closely monitor developments related to the company's clinical-stage biopharmaceutical programs and their potential market impacts. MediciNova is focusing on two main compounds, MN-166 (ibudilast) and MN-001 (tipelukast), which target inflammatory and neurodegenerative diseases. MN-166 is particularly noteworthy as it is advancing into Phase 3 trials for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM), as well as being on the brink of Phase 3 readiness for progressive multiple sclerosis (MS).
Given the significant unmet need in these therapeutic areas, successful outcomes from the ongoing and forthcoming trials could lead to substantial increases in stock value as investor confidence builds. The versatility of MN-166, also being explored for Long COVID and substance dependence, further diversifies MediciNova’s portfolio and market appeal.
However, investors should remain cautious of the inherent risks associated with clinical development. The pathway to regulatory approval is fraught with uncertainties—including potential trial delays, the reliability of partnerships for funding, and the need for additional capital to support operations. These factors could influence stock performance significantly.
As Drs. Iwaki and Crean engage with investors during the conference, their insights on funding strategies and trial progress will be critical. Attending the presentation via the webcast could provide valuable information that could assist in forecasting the company's trajectory in the competitive biopharmaceutical market.
Overall, while MediciNova presents intriguing long-term opportunities, the speculative nature of clinical-stage biotechnology warrants a balanced approach—consider risk appetite and perform thorough due diligence before making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LA JOLLA, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, MD., Ph.D., President and CEO, and David H. Crean, PhD, Chief Business Officer will present a corporate overview at the H.C. Wainwright 27 th Annual Global Investment Conference. The conference is being held on September 8 – 10, 2025 at the Lotte New York Palace Hotel.
| Presentation Date: | September 5, 2025 |
| Time: | Available on-demand beginning at 7:00am ET on September 5, 2025. |
Webcast Link:
A live webcast of the presentation can be accessed on the investor relations section of the MediciNova website. A replay of the webcast will be archived and available following the event for approximately 90 days.
Drs. Iwaki and Crean will be available for one-on-one meetings throughout the conference. To request a meeting and to register for the conference, click below:
https://hcwevents.com/annualconference/
About MediciNova
MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in Long COVID and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and a second Phase 2 trial in non-alcoholic fatty liver disease (NAFLD) is ongoing. MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.
Forward-Looking Statements
Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166 and MN-001. These forward-looking statements may be preceded by, followed by, or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166 and MN-001, and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2024 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.
INVESTOR CONTACT :
David H. Crean, Ph.D.
Chief Business Officer
MediciNova, Inc
info@medicinova.com
FAQ**
What specific updates about MediciNova Inc. (NASDAQ:MNOV) can we expect to hear at the H.C. Wainwright 27th Annual Global Investment Conference, particularly regarding their Phase 3 trials for MN-166 on ALS and DCM?
How is MediciNova Inc. (NASDAQ:MNOV) addressing the financial risks mentioned in their forward-looking statements, especially concerning the funding for MN-166 and MN-001 development?
Given the potential uncertainties in clinical trials for MediciNova Inc. (NASDAQ:MNOV), what strategies do they employ to optimize the likelihood of regulatory approvals for their leading candidates?
Can MediciNova Inc. (NASDAQ:MNOV) provide insights into any strategic partnerships or collaborations currently in place to support the clinical development of its key assets, MN-166 and MN-001?
**MWN-AI FAQ is based on asking OpenAI questions about MediciNova Inc. (NASDAQ: MNOV).
NASDAQ: MNOV
MNOV Trading
-0.72% G/L:
$1.37 Last:
2,419 Volume:
$1.3701 Open:
